Literature DB >> 23907333

Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia.

Dimitrios S Karagiannakis1, Jiannis Vlachogiannakos, Georgios Anastasiadis, Irini Vafiadis-Zouboulis, Spiros D Ladas.   

Abstract

BACKGROUND: The cardiac dysfunction presented in cirrhotic patients is already known as cirrhotic cardiomyopathy. The pathogenesis of this entity is not fully understood. AIMS: The aim of this study was to evaluate the frequency and characteristics of cirrhotic cardiomyopathy and to investigate the possible role of bacterial endotoxemia on its aggravation.
METHODS: Forty-five cirrhotics were studied by a tissue Doppler imaging echocardiography at rest and after stress. The diagnosis of left ventricular diastolic dysfunction was based on the latest guidelines of the American Society of Echocardiography, whereas its severity was defined by the E/e'av ratio. Endotoxemia was estimated by measuring the serum levels of lipopolysaccharide-binding protein (LBP) and cytokines.
RESULTS: None of the patients had systolic dysfunction, but 17/45 (37.8 %) had a diastolic one. Patients with grade II diastolic dysfunction had significantly longer QTc (p = 0.049), larger left atrium volume (p = 0.013), higher Brain Natriuretic Peptide levels (p = 0.007) and higher LBP levels (p = 0.02), compared to those with normal cardiac function, without differences in the systemic hemodynamics and the cytokines' levels. Moreover, the severity of diastolic dysfunction as reflected by the E/e'av. was significantly correlated with the LBP levels (p = 0.002). On the multivariate analysis, the LBP was independently associated with the presence of diastolic dysfunction.
CONCLUSIONS: Cirrhosis is commonly complicated by cardiac dysfunction. Patients with severe cirrhotic cardiomyopathy have higher LBP levels, which are significantly correlated with the degree of diastolic dysfunction. Our findings support a potential role of bacterial endotoxemia on the aggravation of cardiomyopathy in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907333     DOI: 10.1007/s10620-013-2693-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Lipopolysaccharide-binding protein.

Authors:  R R Schumann; E Latz
Journal:  Chem Immunol       Date:  2000

2.  Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.

Authors:  Pablo Bellot; Juan Carlos García-Pagán; Rubén Francés; Juan G Abraldes; Miguel Navasa; Miguel Pérez-Mateo; José Such; Jaime Bosch
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

Review 3.  Cardiac electrophysiological abnormalities in patients with cirrhosis.

Authors:  Andrea Zambruni; Franco Trevisani; Paolo Caraceni; Mauro Bernardi
Journal:  J Hepatol       Date:  2006-01-24       Impact factor: 25.083

Review 4.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

5.  Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats.

Authors:  G Kleber; A Braillon; C Gaudin; B Champigneulle; S Cailmail; D Lebrec
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

Review 6.  Cirrhotic cardiomyopathy.

Authors:  Søren Møller; Jens H Henriksen
Journal:  J Hepatol       Date:  2010-03-31       Impact factor: 25.083

7.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.

Authors:  A Krag; F Bendtsen; J H Henriksen; S Møller
Journal:  Gut       Date:  2010-01       Impact factor: 23.059

9.  Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.

Authors:  J Vlachogiannakos; A S Saveriadis; N Viazis; I Theodoropoulos; K Foudoulis; S Manolakopoulos; S Raptis; D G Karamanolis
Journal:  Aliment Pharmacol Ther       Date:  2009-02-07       Impact factor: 8.171

10.  Endotoxin-induced myocardial dysfunction in senescent rats.

Authors:  Sandrine Rozenberg; Sophie Besse; Hélène Brisson; Elsa Jozefowicz; Abdelmejid Kandoussi; Alexandre Mebazaa; Bruno Riou; Benoît Vallet; Benoît Tavernier
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  15 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

Review 4.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis.

Authors:  Melisa Dirchwolf; Andrés Eduardo Ruf
Journal:  World J Hepatol       Date:  2015-08-08

6.  Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?

Authors:  Mara Barbosa; Joana Guardado; Carla Marinho; Bruno Rosa; Isabel Quelhas; António Lourenço; José Cotter
Journal:  World J Hepatol       Date:  2016-01-28

7.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

Review 8.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 9.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 10.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.